LOG IN
SIGN UP
MARKET
BIIB
BIIB
Biogen Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
204.22
+1.86
+0.92%
After Hours: 204.50 +0.28 +0.14% 16:52 05/26 EDT
OPEN
202.98
PREV CLOSE
202.36
HIGH
205.73
LOW
202.34
VOLUME
531.97K
TURNOVER
0
52 WEEK HIGH
468.55
52 WEEK LOW
187.16
MARKET CAP
29.91B
P/E (TTM)
20.93
1D
5D
1M
3M
1Y
5Y
Ionis Pharmaceuticals' Angelman Syndrome therapy granted orphan drug status
The U.S. FDA has granted orphan drug status to an Ionis Pharmaceuticals (NASDAQ:IONS) antisense oligonucleotide candidate for Angelman Syndrome. The candidate, ION582, is partnered with Biogen (BIIB). In 2021, Ionis (IONS)
Seekingalpha · 9h ago
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Zacks · 1d ago
Biogen Needs a New CEO. Here Are Some Options.
The executive who replaces Michel Vounatsos will inherit a large-cap biotech facing significant challenges.
Barrons.com · 2d ago
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Investor Place · 3d ago
Biogen Releases 2021 Year In Review, Disclosing Progress on Climate, Health and Equity
As a purpose-driven company, Biogen seeks ways to reinforce our commitment to climate, health and equity. Our newly released 2021 Year in Review reports on our progress on these and other prioritie...
News Direct · 3d ago
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Benzinga · 3d ago
Morning Brief: Top Financial Stories Dominating on Monday, May 23
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China
Benzinga · 3d ago
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.
Benzinga · 3d ago
No Data
Learn about the latest financial forecast of BIIB. Analyze the recent business situations of Biogen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 35 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
17.14%Strong Buy
25.71%Buy
54.29%Hold
2.86%Under-perform
0.00%Sell
Analyst Price Target
The average BIIB stock price target is 242.00 with a high estimate of 350.00 and a low estimate of 185.00.
Current 204.22
EPS
Actual
Estimate
1.422.844.265.68
Institutional Holdings
Institutions: 1.46K
Institutional Holdings: 137.06M
% Owned: 93.58%
Shares Outstanding: 146.45M
TypeInstitutionsShares
Increased
296
8.64M
New
131
1.48M
Decreased
381
8.92M
Sold Out
150
1.17M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Stelios Papadopoulos
Chief Executive Officer/Director
Michel Vounatsos
Chief Financial Officer/Executive Vice President
Michael McDonnell
Chief Human Resource Officer/Executive Vice President
Ginger Gregory
Executive Vice President/Secretary
Susan Alexander
Executive Vice President
Alphonse Galdes
Executive Vice President
Chirfi Guindo
Senior Vice President/Chief Accounting Officer
Robin Kramer
Independent Director
Alexander Denner
Independent Director
Caroline Dorsa
Independent Director
William Hawkins
Independent Director
Nancy Leaming
Independent Director
Jesus Mantas
Independent Director
Richard Mulligan
Independent Director
Brian Posner
Independent Director
Eric Rowinsky
No Data
No Data
About BIIB
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.